5-ethyl-8-oxo-5,8-dihydro-thiazolo[5,4-b][1,8]naphthyridine-7-carboxylic acid | 63541-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-ethyl-8-oxo-5,8-dihydro-thiazolo[5,4-b][1,8]naphthyridine-7-carboxylic acid
• 英文别名: 5-Ethyl-8-oxo-[1,3]thiazolo[5,4-b][1,8]naphthyridine-7-carboxylic acid
• CAS: 63541-05-9
• 化学式: C₁₂H₉N₃O₃S
• 分子量: 275.288
• InChiKey: OMUFGNDVWIOELL-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C(Solv: N,N-dimethylformamide (68-12-2))
• 沸点：
  476.7±45.0 °C(Predicted)
• 密度：
  1.573±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-amino-1-ethyl-7-mercapto-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 在 sodium hydroxide 作用下， 以 四氯化碳 、 乙醇 为溶剂， 生成 5-ethyl-8-oxo-5,8-dihydro-thiazolo[5,4-b][1,8]naphthyridine-7-carboxylic acid
  参考文献：
  名称：

  Synthesis of antimicrobial agents. III. Synthesis and antimicrobial activities of thiazolo[5,4-b]naphthyridine derivatives.

  摘要：

  为了寻找新型抗菌剂，合成了一系列含有新环体系的化合物，即2-取代的8-乙基-5，8-二氢-5-氧代噻唑并[5，4-b]萘啶-6-羧酸及其相关衍生物。6-氨基-1-乙基-7-巯基-1，4-二氢-4-氧代萘啶-3-羧酸（2）与酸、酸酐、酰氯和乙基黄原酸酯反应，得到了多种噻唑并[5，4-b]萘啶衍生物。在乙酸中回流乙基7-氯-1-乙基-6-硝基-1，4-二氢-4-氧代萘啶-3-羧酸酯（16）与KSCN，直接得到了噻唑环化产物19。8-乙基-2-甲硫基-5，8-二氢-5-氧代噻唑并[5，4-b]萘啶-6-羧酸（11）与二甲基硫酸反应，根据反应条件的不同，得到了不同的产物（13b、25和26）。本工作中合成的一些化合物在体外对革兰氏阴性和革兰氏阳性细菌显示出高活性。

  DOI：

  10.1248/cpb.27.410

文献信息

• ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20100249030A1

  公开（公告）日：2010-09-30

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.

  本发明涉及一种通过预先使用抗有丝分裂剂，然后再使用至少一种极化素激酶抑制剂来治疗癌症的方法。详细说明了在本发明治疗中有用的抗有丝分裂剂和极化素激酶抑制剂。
• SUZUKI N.; DOHMORI R., CHEM. AND PHARM. BULL., 1979, 27, NO 2, 410-418
  作者：SUZUKI N.、 DOHMORI R.

  DOI：——

  日期：——
• [EN] ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT<br/>[FR] COMBINAISON D'AGENT ANTIMITOTIQUE ET D'INHIBITEUR DE L'AURORA KINASE COMME TRAITEMENT ANTI-CANCER
  申请人：SCHERING CORP

  公开号：WO2009017701A2

  公开（公告）日：2009-02-05

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.
• Synthesis of antimicrobial agents. III. Synthesis and antimicrobial activities of thiazolo[5,4-b]naphthyridine derivatives.
  作者：NORIO SUZUKI、RENZO DOHMORI

  DOI：10.1248/cpb.27.410

  日期：——

  In order to search for new antimicrobial agents, a number of 2-substituted 8-ethyl-5, 8-dihydro-5-oxothiazolo [5, 4-b] naphthyridine-6-carboxylic acid and their related compounds which consist of a new ring system were prepared. Reactions of the 6-amino-1-ethyl-7-mercapto-1, 4-dihydro-4-oxonaphthyridine-3-carboxylic acid (2) with acid, acid anhydride, acid chloride and ethylxanthate afforded several thiazolo [5, 4-b] naphthyridine derivatives. Refluxing ethyl 7-chloro-1-ethyl-6-nitro-1, 4-dihydro-4-oxonaphthyridine-3-carboxylate (16) with KSCN in acetic acid gave directly the thiazole cyclization product 19. Reaction of 8-ethyl-2-methylthio-5, 8-dihydro-5-oxothiazolo [5, 4-b] naphthyridine-6-carboxylic acid (11) with dimethyl sulfate gave various products (13b, 25 and 26) depending upon its reaction conditions. Some compounds obtained in this work exhibited high activities against gram-negative and gram-positive bacteria in vitro.

  为了寻找新型抗菌剂，合成了一系列含有新环体系的化合物，即2-取代的8-乙基-5，8-二氢-5-氧代噻唑并[5，4-b]萘啶-6-羧酸及其相关衍生物。6-氨基-1-乙基-7-巯基-1，4-二氢-4-氧代萘啶-3-羧酸（2）与酸、酸酐、酰氯和乙基黄原酸酯反应，得到了多种噻唑并[5，4-b]萘啶衍生物。在乙酸中回流乙基7-氯-1-乙基-6-硝基-1，4-二氢-4-氧代萘啶-3-羧酸酯（16）与KSCN，直接得到了噻唑环化产物19。8-乙基-2-甲硫基-5，8-二氢-5-氧代噻唑并[5，4-b]萘啶-6-羧酸（11）与二甲基硫酸反应，根据反应条件的不同，得到了不同的产物（13b、25和26）。本工作中合成的一些化合物在体外对革兰氏阴性和革兰氏阳性细菌显示出高活性。